Pages that link to "Q34467576"
Jump to navigation
Jump to search
The following pages link to The metabolic syndrome as a predictor of nonalcoholic fatty liver disease (Q34467576):
Displaying 50 items.
- Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals (Q22299426) (← links)
- Herbal medicines for fatty liver diseases (Q24200256) (← links)
- Herbal medicines for fatty liver diseases (Q24236298) (← links)
- Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic (Q24563381) (← links)
- The blind men 'see' the elephant-the many faces of fatty liver disease (Q24654991) (← links)
- Association between white blood cell count and non-alcoholic fatty liver disease in urban Han Chinese: a prospective cohort study (Q24658538) (← links)
- Hepatitis C Virus, Insulin Resistance, and Steatosis (Q26751755) (← links)
- NAFLD and Chronic Kidney Disease (Q26752759) (← links)
- Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome (Q26765455) (← links)
- Metabolic syndrome in rheumatoid arthritis (Q26822038) (← links)
- Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease (Q26827665) (← links)
- Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine (Q26992163) (← links)
- The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know (Q27008277) (← links)
- Epidemiology of the metabolic syndrome in the USA (Q28298801) (← links)
- Autophagy in the liver: cell's cannibalism and beyond (Q28388115) (← links)
- High serum uric acid increases the risk for nonalcoholic Fatty liver disease: a prospective observational study (Q28474831) (← links)
- Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults (Q29614911) (← links)
- The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (Q29617157) (← links)
- HIV and its relationship to insulin resistance and lipid abnormalities. (Q30239101) (← links)
- What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? (Q30361645) (← links)
- Multifeature analysis of an ultrasound quantitative diagnostic index for classifying nonalcoholic fatty liver disease. (Q30371936) (← links)
- Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease. (Q30433234) (← links)
- Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)? (Q30443852) (← links)
- Fatty pancreas, insulin resistance, and β-cell function: a population study using fat-water magnetic resonance imaging (Q30747665) (← links)
- Domain Analysis of Integrated Data to Reduce Cost Associated with Liver Disease. (Q30986369) (← links)
- Association of hormonal dysregulation with metabolic syndrome in older women: data from the InCHIANTI study (Q31060630) (← links)
- Detection of changes in the structure and distribution map of triacylglycerol in fatty liver model by MALDI-SpiralTOF. (Q31154276) (← links)
- Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma (Q33397694) (← links)
- The metabolic syndrome (Q33569142) (← links)
- Benefits of Levothyroxine Replacement Therapy on Nonalcoholic Fatty Liver Disease in Subclinical Hypothyroidism Patients (Q33573638) (← links)
- Validation of endogenous reference genes for qRT-PCR analysis of human visceral adipose samples (Q33584317) (← links)
- Endogenous catalase delays high-fat diet-induced liver injury in mice. (Q33614752) (← links)
- Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients (Q33627037) (← links)
- Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: A post hoc analysis of a cohort study (Q33644131) (← links)
- Enhanced amelioration of high-fat diet-induced fatty liver by docosahexaenoic acid and lysine supplementations (Q33748530) (← links)
- Overexpression of apolipoprotein A-I alleviates endoplasmic reticulum stress in hepatocytes (Q33755805) (← links)
- Metabolic syndrome: is equine disease comparable to what we know in humans? (Q33796880) (← links)
- PPARalpha: energy combustion, hypolipidemia, inflammation and cancer (Q33805104) (← links)
- Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile (Q33820345) (← links)
- NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. (Q33844463) (← links)
- Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease (Q33886948) (← links)
- Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease (Q33895173) (← links)
- Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes. (Q33937311) (← links)
- Prevalence of metabolic syndrome and risks of abnormal serum alanine aminotransferase in Hispanics: a population-based study. (Q33947985) (← links)
- Metabolic syndrome, C-reactive protein, and mortality in U.S. Blacks and Whites: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study (Q33960247) (← links)
- Clinical correlation of nonalcoholic fatty liver disease in a Chinese taxi drivers population in Taiwan: Experience at a teaching hospital (Q34005976) (← links)
- Physical activity and risk of fatty liver in people with different levels of alcohol consumption: a prospective cohort study (Q34024582) (← links)
- Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training (Q34031701) (← links)
- GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes (Q34041838) (← links)
- Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database (Q34077811) (← links)